Profusa Expands in Europe with French Vascular Surgery Leader
Paris partnership brings Lumee Oxygen monitoring to practices covering 8% of France’s CLTI cases.
Profusa (NASDAQ: PFSA) is extending its footprint in European healthcare with the addition of one of France’s top vascular surgeons to its customer base. The company announced this week that Pr. Yann Gouëffic, M.D., Ph.D., professor of vascular surgery at Groupe Hospitalier Paris Saint Joseph, will adopt Profusa’s Lumee™ Oxygen monitoring technology for use in both his practice and clinical studies.
The collaboration marks a significant milestone for the digital health firm, as Gouëffic and his affiliates treat approximately 8% of all critical limb-threatening ischemia (CLTI) cases in France. CLTI, a severe form of peripheral arterial disease, affects thousands of patients annually and often leads to amputation if not properly managed.
A Surgeon’s Endorsement
Pr. Gouëffic, who has more than two decades of experience in treating peripheral arterial diseases, described the technology as transformative. “My practice, in addition to those of my affiliates, treats a meaningful number of CLTI cases in France, and I believe Profusa’s Lumee technology to be a game changer in our patient care program and a true advancement clinical disease governance,” he said.
He emphasized the importance of continuous monitoring, not only during surgical intervention but also throughout the recovery process. “Real-time oxygen monitoring data for patients suffering from CLTI, while critical during surgery, is equally as important during recovery at home. Given the large clinical need, I believe offering Lumee to our patients will result in improved outcomes,” Gouëffic added.
Also Read: Why Nvidia’s Tech Investments Could Transform the Entire AI Innovation Ecosystem
Strengthening Profusa’s Market Reach
Based in Berkeley, California, Profusa develops tissue-integrated biosensors designed to provide continuous, medical-grade data that supports clinical decision-making. The addition of Gouëffic, who also leads the FRANCE-PAD network of six high-volume hospitals, significantly increases the company’s influence in Europe. Collectively, his network represents around 8% of lower limb peripheral artery disease treatments across the country.
Ben Hwang, Ph.D., Chairman and CEO of Profusa, welcomed the new collaboration, stating:
“Our Lumee oxygen monitoring system continues to be validated with the steady addition of new surgeon customers to our network. We warmly welcome Pr. Gouëffic and look forward to advancing vascular disease management with our commercial and clinical collaboration. We are also excited to serve Pr. Gouëffic’s affiliates, which, all combined, account for approximately 8% of CLTI cases in France. We believe we provide a differentiated, real-time biochemistry monitoring platform technology for use at the clinic and at home, and are focused on serving a large endovascular market need, estimated at over 300,000 procedures a year in Europe.”
A Growing Opportunity
The European market for endovascular procedures is estimated at more than 300,000 annually, and Profusa sees Lumee as a differentiated solution to meet this demand. The company’s strategy includes building partnerships with leading physicians to accelerate the adoption of its monitoring platform, both in hospitals and in patients’ homes.
By aligning with Gouëffic and his affiliates, Profusa gains access to a large population of patients who may benefit from real-time oxygen monitoring. This step not only strengthens the company’s European expansion but also reinforces its commitment to tackling complex vascular conditions with innovative technology.
Read Next: Why Big Investors Who Can’t Buy Crypto Are Gobbling Up These Stocks Instead
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $190,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
